(homidium bromide) and Prothidium (pyrithidium bromide) for the treatment and prophylaxis of trypanosomiasis in cattle, and we also discovered and developed Entamide (diloxanide) and later Furamide (diloxanide furoate) for the treatment of ameebiasis, and these are still produced and sold in the areas where these diseases are problems. But at present my department's programme is concerned with pharmacologically active synthetic chemicals tackling diseases such as rheumatoid arthritis, peptic ulceration, cardiovascular disease and mental disorders. We ourselves do not test compounds against cancer but, like many other companies, we submit compounds for testing to the National Cancer Institute of the National Institutes of Health in the USA, believing that this is the best way for a company of our size to help with this disease. There are of course some of the larger companies still working on tropical diseases, and contributions by the pharmaceutical industry in general and British companies in particular to the pharmacopoeia of physicians working in the tropics have been considerable. However, with the extremely high cost involved in developing new drugs the companies have to decide what part of their resources can be devoted to such areas. It is of interest that the WHO is now considering the possibility of helping to sponsor research in tropical medicine. There is also the possibility of collaboration between bodies such as the MRC and the pharmaceutical industry to look at less common diseases as well as tropical diseases.
In summary, project selection is very much an individual matter for each company, and the factors concerned are a mix of financial and technical ones. Research directors are concerned to do their best for their companies and for the community.
The need to export has affected our choice of projects to some extent, and the pharmaceutical industry has made a considerable contribution to the balance of payments. If we are allowed to expand profitably then I am sure the choice can be widened and the less common diseases tackled. In the meantime I welcome any opportunity presented to look at collaborative research with any other body. I also welcome the opportunity presented by this Forum to discuss these problems and look for solutions. Such solutions must remain in the hands of the pharmaceutical industry and our colleagues in medicine, and be protected from the doctrinaire approach of the politician. It is accepted that research is a very high-risk activity, at least as far as the discovery of genuine new active drugs is concerned -both on account of the high uncertainty of its outcome and the considerable lead times involved. In spite of this it is to research fhat the internationally based drug company looks for its major revenueearning products. Because of the key role of research in the success of the company as a whole the level of investment and selection of fields of research represents crucial decisions for research and development management.
The overall failure rate of compounds between synthesis and the market is, of course, very highthe National Economic Development Office study in 1972 assessed the failure rate at 99.99%. However, the time scale involved is perhaps of even greater importance in selecting areas for future research.
Today it takes about 15 years frsom the original idea or concept to the widespread use of a new drug. The initial investigational studies are almost invariably based on some known basic or scientific or medical knowledge so that to project too far ahead of existing frontiers would be unprofitable. Hence about 20 years is an appropriate time span over which to consider the selection of research projects in the pharmaceutical industry. The key factor in any selection for research areas should be the future medical and social need for new drugs. Therefore a prerequisite must be an estimate of the medical and social needs some 20 years hence in order that (irrespective of which research project is chosen) the conceptual ideas of the present are appropriate and geared to this future. One is led, therefore, to the inescapable conclusion that the new drugs in the twenty-first century will originate from ideas in the next few years. From a research point of view, the year 2000 is almost upon us.
It is not appropriate here to discuss in depth the various routes by which new drugs are obtained; the relative emphasis placed on them is a combination of individual research philosophy and the particular needs of a given pharmaceutical company, and I will deal later with our .own particular research philosophy. Of course, some of the greatest problems concern the brain and the mind. We must achieve an understanding of the mechanisms of intelligence and learning so that we can identify the faults which underlie mental illness. Most of the present drug advances in psychiatry have been by 'serendipitous' leads in clinical research.
But even when substantially all disease has been brought under control, there would still be a need for pharmaceutical research, because there would remain a need to find the means for controlling normal function: for example, the control of intellectual development. As the world becomes an increasingly complex place in which to live, and as the speed of change accelerates, we are going to need more and more able people to control events, so we need to discover how to hasten the learning process. We may not have time in the future for our present rather slow training programmes. We shall need to be able to put younger people in charge of demanding processes and situations before they have spent something like a third of their life span at school and university or in apprenticeship. We It seems to me that the products of the industry today lead to innovation of improved products for treatment of diseases in the future. In order to achieve profitability it is the greatest good for the greatest number that is the important criterion. The industry provides medicines where it is obvious that they are needed -for instance, antibiotics in a country where bronchitis is endemic. But what about minor diseases? What guides companies to cater for small, less revenueproducing enterprises which might, in terms of human need, be extremely valuable to a number of individuals?
Dr Cox: Success is not determined solely by 'profitability'. Success can be measured in a number of ways, including the financial. Dr Main mentioned the success of the people doing the work and the motivation and satisfaction which they receive from seeing illness healed. One cannot talk purely in terms of profitability but there has to be financial success in order for the company to invest further money in research. Mr Smith asked how we decide to go into areas in which there is not much potential for financial success, but in which there may be a great medical need -the short answer is that we do not. Fortunately, or unfortunately, whichever way one looks at it, there is such a large range of. medical problems that are worth tackling that we can pick those problems which meet all the criteria of success. When we reach a stage at which all the problems are solved -or almost all, so that only a few are left, the question will arise.
At the nmoment we are able to select those problems which will meet all the criteria of success, and one of the most important criteria is certainly financial.
Sir John Richardson (London): Dr Main mentioned briefly that he thought there was some cooperation possible between the MRC and the industry in the field of the less common diseases. Would he like to take up that point?
Dr Main: We have held one meeting with research directors from the industry and attempts are being made to arrange another meeting soon. On the agenda for that meeting is the discussion of the less common complaints, and also tropical diseases. We should like to listen and help where we can. We can get into the less common diseases if the technology is available. Most of our research is objective-orientated. However, sometimes one sets off to do a certain thing but something turns up which does not meet the objective but which looks very interesting. For example, if we came across something which might affect demyelinating diseases we would certainly investigate it.
Dr D Jack (Allen & Hanbury Research Ltd, Ware): One often hears about this problem of uncommon diseases which are inadequately investigated. I should be grateful if the physicians present could tell me about these diseases, on which we should be working. Often, people who talk about uncommon diseases illustrate their case by mentioning multiple sclerosis. The reason we do not work on the problem of multiple sclerosis -at least in Allen & Hanbury Researchis not because there is not a great need for a new drug, but simply that we do not know how to start to find it. I think that is true of most of the uncommon diseases. In order to start research work there has to be some working proposition about the disease, or about the nature of cellular control mechanisms which are likely to affect the progress of the disease. By and large, the best projects are those in which the cellular control mechanisms are chemically defined because, otherwise, it is difficult to make progress.
There are many great problems affecting mankind. Indeed, with the possible exception of acute infections and a few specific deficiency diseases, I cannot think of any common human ailments which are particularly well treated today. We ought not to waste our time talking about rare diseases. Thirdly, Dr Herxheimer suggested that it was a bad thing for a number of drugs for a similar condition to appear on the market at the same time. I wonder whether it really is, because if research were limited to one company, there would be only one 'chance', as it were, of improving therapy for patients with the particular disease. On the other hand, if there are three, four or five, there is a real possibility that both qualitative and quantitative differences will occur between-the drugs that are marketed, and that the patients will benefit by having a choice of several drugs.
All of us know that even if one of those drugs ends up by doing the greatest good for the greatest number, some of the others will be extremely useful alternative drugs and therefore have a place in therapy too.
However, duplication is becoming less common. As research is becoming so expensive, and as research teams tend to build up special expertise, as we have heard today, there is a tendency for cooperation, not only with the MRC and similar bodies, but between companies themselves. We now have a number of cases in which two, sometimes even three companies get together and pool their resources and experiences so as to have the optimum chance of producing a new drug for research. We have done this, and I know that a number of other companies have. It seems to be a way in which the expertise available in the industry comes together and gives the greatest chance of producing a new drug. Unfortunately, of course, once the two companies have produced the drug, the decision then has to be made about which one will market it. It seems only reasonable, if two companies pool their resources to carry out research in this way, that both should be allowed to market the new drug. Once that happens there follow .the usual criticisms of two companies marketing the same drug.
Professor R H Girdwood (University Department of Therapeutics, Royal Infirmary, Edinburgh): Occasionally, in postgraduate lectures I refer to Factor XIII deficiency. I would not have known that Dr Cromie had a drug to treat it if I had not come here today.
Mr S M Peretz (Cyanamnid of Great Britain Ltd, Gosport, Hampshire): Somebody wrote the other day that presidents of the ABPI have to be replaced every two years because they get so bored with hearing the same uninformed criticisms from laymen about the industry. One of the common criticisms that is made, on which Dr Cromie has touched, is that we as an industry, because we are so highly competitive, have no interest in rationalizing our research programmes. It is thought that if somebody in authority could bang the industry about the head, tell one company to deal with rheumatoid arthritis, a second with asthma and a third with infectious diseases, no two companies should be doing research on the same lines and all would be well. This criticism is commonly ntade; I should like to hear the speakers comment on it. Dr Cox.: Even within our own research organization we have competitive approaches to the same drug. If we could be certain that there was only one way in which to find a drug in any particular therapeutic area, the argument would be valid. There are many different approaches to the same problem, and the competitive spirit is an extremely important aspect in determining success.
The fact that we are competing with colleagues within our own research organization as well as outside is an important factor in success. Competition leads to success more quickly.
Dr E H Harries (Association of British Pharmaceutical Industry, London): The word has not yet been used this afternoon, but 'serendipity' is extremely important in this. No matter what the inventive chemist may have done, it is the observant biologist who may cause objectives to be changed. If one company is active in a field, such as asthma, but finds a lead which suggests that this drug would be useful in rheumatoid arthritis, that company will move in that direction. People cannot be directed into going in one way only.
Dr Jack: I wanted to say a few words about restricting the number of research organizations, so that they might be bigger and might specialize in particular areas. People who propose this kind of thing have failed to understand that sound ideas simple enough to be reduced to practice are the real limiting factors for progress in the finding of new drugs. I might be convinced by their argument if I thought that centralization would be likely to increase the number of such ideas. But, frankly, I have no reason to suppose so. Ideas come from individuals, and the more individuals who are free to express themselves, the better the chance of something worth while emerging. In fact, I can think of extremely few drugs that have been discovered as a result of a major set piece by a large organization; but I can think of a fair number of set pieces that have failed.
The onus should be on the proposers of this kind of change to prove how centralization of drug research would be more productive than what we have now.
Dr Herxheimer: The arguments against centralization are quite convincing, but the problem is not quite as simple as Dr Cromie made it sound: namely, one may usefully like to have, say, four drugs available which do a particular thing. The first one may help 60% of the people, the second another 20 %, the third another 10 % and so on. But when we have arrived at five drugs, that is enough. How can we stop the sixth to the twelfth drugs of the same kind being marketed? This is the kind of situation which leads people to talk about cutting out wasteful research. There is a simple way of cutting it out which is not to allow the sixth to the twelfth drugs to be marketed. That research would then fold up automatically without any sort ofcentralization because it would not be rewarded.
Dr Cromie: One of the problems which people may find difficult to understand is that they think we market drugs with full knowledge of all their properties, adverse reactions, interactions and so on. Unfortunately, this is absolutely untrue. By the time we market a drug, we have experience of it in a relatively small number of patients, often under relatively artificial conditions. We certainly do not have experience of the drug used in normal clinical practice in patients in their tens of thousands.
Therefore, when we market a drug, we really know relatively little about it. It is absolutely impossible to say, at the stage when a drug is being marketed, how it will measure up to the other drugs available at that time. The only way to find this out is to allow it to be used on a widespread scale. Once they have been used in that way all drugs find their true position. I can think of many examples -and I am sure that Dr Herxheimer can also -where there were developments in a certain field and it might almost have been said that we had come to the end of progress in that fieldthen, a relatively small modification of a molecule produces a dramatic change. It is always this unexpected enormous leap, or sometimes a series of smaller leaps, which produce therapeutic benefit that would never have come about if this sort of premarketing selection had been allowed, as suggested by Dr Herxheimer.
Another point against centralized direction of research is that decisions taken by any sort of centralized function tend to be compromise decisions. It is only an individual who will take his courage in both hands and follow a lead all the way through, committing to it enormous funds, people, and so on.
All who talk about research in the pharmaceutical industry today, must recognize this tremendous responsibility and the contribution now being taken by research directors. It is becoming increasingly difficult because of the increased time and expenditure. I cannot see any centralized, semi-bureaucratic system ever taking that responsibility, pushing it through and getting the results we are obtaining today.
Dr Cox: Research is an extremely high-risk area and unless one feels in control of all the factors, one is very unlikely to take decisions of this sort. We all know the problems that arise if decisions on research projects are put to a large committee. Certainly the initial decisions are best taken by key individuals with the benefit of advice from many quarters, because there are enormous barriers to overcome before a drug or an idea becomes accepted and is successful. Anything which destroys the individuality, as far as research is concerned, will certainly destroy its creativity too. Dr Main: There are many definitions of development, but perhaps we might define it as all those activities which take place after the discovery, all of which allow the drug to appear. What we have done is to gear ourselves to doing research and development. I can think of few bodies outside the pharmaceutical industry which can do the complete job of making the discovery and making the drug available. Everyone has a right to discover new drugs. We should love to develop them if others are interested in discovering them.
Mr Peretz: Perhaps it is not sufficiently generally known -although there are some representatives here from Glaxo who are well 'aware of the facts of the matter -that cephalosporin, which is now the major revenue-producer for the NRDC, may have been the discovery of the NRDC but it would not have been worth one penny without the development work which has been done by companies such as Glaxo, Lilly and many other pharmaceutical companies to produce a usable, prescribable drug. I should like to firmly endorse what Dr Main has just said.
Sir John Richardson: Can you elaborate a little for us on any possibilities for a profitable, proper commercial extension into these areas where collaboration with official bodies is really so absolutely vital?
Dr Main: The record ofthe industry in tropical diseases has been a good one. There are still companies working in the area of tropical medicine -and I wish them well. They obviously feel that they will get the returns. Thirdly, I do not think companies avoid tropical medicine because it is difficult. As someone who joined the industry to do tropical medicine, let me say that I think it is an easy area for drug research. On the whole there is an organism, a parasite, a worm or something like that, and an attempt is made to kill it withou't killing the host. There is a relatively simple model on which work can be done. It is not that the technology is not there.-But in certain tropical areas we have seen whole businesses disappear overnight. Therefore, there is some hesitation about putting major research projects into tropical medicine.
The WHO has set up some working groups to consider the possibility of helping at the development stage -if certain companies are prepared to do the experimental model testing. The suggestion is that the WHO would then be prepared to put in finance at the development stage. This is something at which we should look carefully. Possibly some companies will wish to collaborate in this way.
Dr Jack: One of the reasons why we in the Glaxo group have not worked recently to any extent on tropical diseases is that we see the problem mainly as sociological rather than specifically medical because the problem is, in principle, solvable within existing technology. Unfortunately, it is difficult, even in the Western world, to have drugs used correctly. It is even more difficult in underdeveloped countries. I think that what money is available to help the underdeveloped countries should go towards dealing with sociological problems -changing their agriculture, plumbing &c. -rather than into research for improved medicines. It would do more good if used in that way.
Mr Peretz: Mr Boden and I were part of a pharmaceutical team that went to China in November 1975.
I thought that what we saw in that country bore out absolutely what Dr Jack says. The success China has had in tackling its tropical diseases -such diseases as schistosomiasis -has come almost entirely from the use of simple hygenic measures, certainly much more than from the use of medicine. The Chinese are a large part of the world's population and seem to be prepared to accept the disciplines that are needed to tackle the problems in that sort of way. I am not quite so sure that the same solution could be adopted in darkest Africa.
Sir John Richardson: Yes, there is absolutely no question that the great advances are the sociological ones. In many ways, the advances in this country in health have been based on sociological factors.
